https://doi.org/10.4081/monaldi.2024.3203
Diffuse alveolar hemorrhage: a retrospective study from a tertiary care center
Submitted: September 13, 2024
Accepted: September 17, 2024
Published: October 28, 2024
Accepted: September 17, 2024
Abstract Views: 94
PDF_EARLY VIEW: 15
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Diffuse alveolar hemorrhage (DAH) is characterized by a syndrome of alveolar bleeding, a fall in hemoglobin, and respiratory failure. It can occur because of various immunologic and non-immunologic conditions. The etiology of DAH is important, as treatment varies with the etiology. This retrospective observational study evaluates the diverse etiologies, time to diagnosis from symptom onset, management strategies, and outcome of DAH in a span of 12 months at our tertiary care center. A total of 8 patients were identified with 8 different etiologies. 6/8 (75%) patients had immunologic causes, and 2/8 (25%) had non-immunologic causes of DAH. 6/8 (75%) patients were females, the mean time to DAH diagnosis was 4.25 months from symptom onset, 6/8 (75%) patients improved, and 2/8 (25%) died due to complications. It is necessary to differentiate between the etiologies of DAH and establish an early diagnosis to plan management and improve outcomes.
Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest 2010;137:1164-71.
DOI: https://doi.org/10.1378/chest.08-2084
Gallagher H, Kwan JT, Jayne DR. Pulmonary renal syndrome: a 4-year, single-center experience. Am J Kidney Dis 2002;39:42-7.
DOI: https://doi.org/10.1053/ajkd.2002.29876
Quadrelli S, Dubinsky D, Solis M, et al. Immune diffuse alveolar hemorrhage: clinical presentation and outcome. Respir Med 2017;129:59-62.
DOI: https://doi.org/10.1016/j.rmed.2017.06.003
Collard HR, Schwarz MI. Diffuse alveolar hemorrhage. Clin Chest Med 2004;25:583-92.
DOI: https://doi.org/10.1016/j.ccm.2004.04.007
Park MS. Diffuse alveolar hemorrhage. Tuberc Respir Dis 2013;74:151-62.
DOI: https://doi.org/10.4046/trd.2013.74.4.151
de Prost N, Parrot A, Picard C, et al. Diffuse alveolar haemorrhage: factors associated with in-hospital and long-term mortality. Eur Respir J 2010;35:1303-11.
DOI: https://doi.org/10.1183/09031936.00075309
Alexandre AT, Vale A, Gomes T. Diffuse alveolar hemorrhage: How relevant is etiology? Sarcoidosis Vasc Diffuse Lung Dis 2019;36:47-52.
lbelda SM, Gefter WB, Epstein DM, Miller WT. Diffuse pulmonary hemorrhage: a review and classification. Radiology 1985;154:289-97.
DOI: https://doi.org/10.1148/radiology.154.2.3155569
Kumasaka S, Kumasaka Y, Jingu A, Tsushima Y. Diagnostic value of “hyperdense consolidation sign” as a characteristic new computed tomography sign of diffuse alveolar hemorrhage. Sci Rep 2022;12:21143.
DOI: https://doi.org/10.1038/s41598-022-25740-y
Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 2018;378:2010-21.
DOI: https://doi.org/10.1056/NEJMra1705454
Yachoui R, Sehgal R, Amlani B, Goldberg JW. Antiphospholipid antibodies-associated diffuse alveolar hemorrhage. Semin Arthritis Rheum 2015;44:652-7.
DOI: https://doi.org/10.1016/j.semarthrit.2014.10.013
Deane KD, West SG. Antiphospholipid antibodies as a cause of pulmonary capillaritis and diffuse alveolar hemorrhage: a case series and literature review. Semin Arthritis Rheum 2005;35:154-65.
DOI: https://doi.org/10.1016/j.semarthrit.2005.05.006
Scheiman Elazary A, Cohen MJ, Aamar S, et al. Pulmonary hemorrhage in antiphospholipid antibody syndrome. J Rheumatol 2012;39:1628-31.
DOI: https://doi.org/10.3899/jrheum.120205
Cartin-Ceba R, Peikert T, Ashrani A, et al. Primary antiphospholipid syndrome–associated diffuse alveolar hemorrhage. Arthritis Care Res 2014;66:301-10.
DOI: https://doi.org/10.1002/acr.22109
Onuk T, İpek G, Karataş MB, et al. Diffuse alveolar hemorrhage after clopidogrel use. Balkan Med J 2016;33:719-20.
DOI: https://doi.org/10.5152/balkanmedj.2016.151545
Soriano R, Al-Rawaf S, Diab K. Diffuse alveolar haemorrhage: a rare complication of clopidogrel use. BMJ Case Rep 2021;14:e244314.
DOI: https://doi.org/10.1136/bcr-2021-244314
Khilnani GC, Tiwari P, Goyal A, Singh L, Arora A, Guleria R. A rare case of pulmonary alveolar hemorrhage with cardiomyopathy. Chest 2018;142:463A.
DOI: https://doi.org/10.1378/chest.1389689
Saha BK. Idiopathic pulmonary hemosiderosis: A state of the art review. Respir Med 2021;176:106234.
DOI: https://doi.org/10.1016/j.rmed.2020.106234
Iwasaki K, Matsuzawa Y, Wakabayashi H, et al Diffuse alveolar haemorrhage with suspected idiopathic pulmonary hemosiderosis and decrease in lung diffusing capacity and chronic respiratory failure BMJ Case Rep 2021;14:e242901.
DOI: https://doi.org/10.1136/bcr-2021-242901
Zamora MR, Warner ML, Tuder R, Schwarz MI. Diffuse alveolar hemorrhage and systemic lupus erythematosus: clinical presentation, histology, survival, and outcome. Medicine 1997;76:192-202.
DOI: https://doi.org/10.1097/00005792-199705000-00005
de Prost N, Parrot A, Cuquemelle E, et al. Diffuse alveolar hemorrhage in immunocompetent patients: etiologies and prognosis revisited. Respir Med 2021;106:1021-32.
DOI: https://doi.org/10.1016/j.rmed.2012.03.015
How to Cite
Mohan, Sanchit, Rohit Kumar, Pranav Ish, Rajnish Kaushik, Tanmaya Talukdar, Neeraj Gupta, and Nitesh Gupta. 2024. “Diffuse Alveolar Hemorrhage: A Retrospective Study from a Tertiary Care Center”. Monaldi Archives for Chest Disease, October. https://doi.org/10.4081/monaldi.2024.3203.
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Gian Francesco Mureddu, Current multivariate risk scores in patients undergoing non-cardiac surgery , Monaldi Archives for Chest Disease: Vol. 87 No. 2 (2017)
- M. Marvisi, L. Balzarini, C. Mancini, P. Mouzakiti, A new type of Hypersensitivity Pneumonitis: salami brusher’s disease , Monaldi Archives for Chest Disease: Vol. 77 No. 1 (2012): Pulmonary series
- P. Trerotoli, N. Bartolomeo, A.M. Moretti, Hospitalisation for COPD in Puglia: the role of hospital discharge database to estimate prevalence and incidence , Monaldi Archives for Chest Disease: Vol. 69 No. 3 (2008): Pulmonary series
- Cleante Scarduelli, Francesco Inglese, Massimiliano Beccaria, Fabio Spreafico, Martina Garuti, Antonietta Pecoriello, Giulia Cervi, Graziana Greco, Sara Scarduelli, Giuseppe Lucchini, Giuseppe De Donno, Claudio Borghi, Pulmonary embolism in patients with severe COVID-19 treated with intermediate- to full-dose enoxaparin: A retrospective study , Monaldi Archives for Chest Disease: Vol. 91 No. 3 (2021)
- Kranti Garg, Karan Sharma, Aditi Gupta, Vishal Chopra, Association of cycle threshold values of CBNAAT with severity and outcome in COVID-19 , Monaldi Archives for Chest Disease: Vol. 91 No. 4 (2021)
- I.P. Neuringer, S.H. Randell, Lung Stem Cell Update: Promise and Controversy , Monaldi Archives for Chest Disease: Vol. 65 No. 1 (2006): Pulmonary series
- M. Bugiani, S. Bonora, A. Carosso, P. Piccioni, M. Cavallero, A. Mondo, V. Ghisetti, The effect of antituberculosis treatment on interferon-γ release assay results , Monaldi Archives for Chest Disease: Vol. 75 No. 4 (2011): Pulmonary series
- Sameer Vaidya, Dipti Gothi, Mahismita Patro, COPD sleep phenotypes: Genesis of respiratory failure in COPD , Monaldi Archives for Chest Disease: Vol. 92 No. 2 (2022)
- C. Ortolani, F. Agostinis, S. Amoroso, R. Ariano, A. Barbato, M. Bassi, G. Cadario, P. Campi, F. Cardinale, G. Ciprandi, R. D’Anneo, M. Di Gioacchino, V. Di Rienzo, A. Fiocchi, M. Galimberti, E. Galli, M. Giovannini, C. Incorvaia, S. La Grutta, C. Lombardi, F. Marcucci, G. Marseglia, M. Minelli, A. Musarra, E. Nettis, E. Novembre, G. Pajno, G. Patriarca, F. Pezzuto, P. Piras, S. Pucci, A. Romano, C. Romano, O. Quercia, G. Scala, D. Schiavino, G. Sforza, M. Tosca, S. Tripodi, F. Frati, Practice parameters for sublingual immunotherapy , Monaldi Archives for Chest Disease: Vol. 65 No. 1 (2006): Pulmonary series
- C. Incorvaia, F. Frati, P. Puccinelli, G.G. Riario-Sforza, S. Dal Bo, Dose dependence of efficacy and safety of subcutaneous immunotherapy , Monaldi Archives for Chest Disease: Vol. 65 No. 1 (2006): Pulmonary series
<< < 27 28 29 30 31 32 33 34 35 36 > >>
You may also start an advanced similarity search for this article.
